Pathophysiology and Treatment of Psychosis in Parkinson’s Disease

[1]  Lauterbach Ec.  Dopaminergic hallucinosis with fluoxetine in Parkinson's disease. , 1993 .

[2]  S. Leurgans,et al.  Genetic variation analysis in parkinson disease patients with and without hallucinations: case-control study. , 2001, Archives of neurology.

[3]  Chiung-Chu Chen,et al.  Short-term effect of bilateral subthalamic stimulation for advanced Parkinson's disease. , 2003, Chang Gung medical journal.

[4]  S. Leurgans,et al.  Poor visual discrimination and visual hallucinations in Parkinson's disease. , 1998, Clinical neuropharmacology.

[5]  J. Friedman,et al.  Atypical antipsychotics in the treatment of drug‐induced psychosis in Parkinson's disease , 2000, Movement disorders : official journal of the Movement Disorder Society.

[6]  E. Kraft,et al.  Visual hallucinations, white matter lesions and disease severity in Parkinson's disease , 1999, Acta neurologica Scandinavica.

[7]  I. McKeith,et al.  Neuroleptic sensitivity to risperidone in Lewy body dementia , 1995, The Lancet.

[8]  G. Stebbins,et al.  Intravenous levodopa in hallucinating Parkinson's disease patients , 1998, Neurology.

[9]  G. Wooten,et al.  Prospective study of hallucinations and delusions in Parkinson's disease , 2001, Journal of neurology, neurosurgery, and psychiatry.

[10]  Jason Noel.  ASHP therapeutic position statement on the use of second-generation antipsychotic medications in the treatment of adults with psychotic disorders. , 2007, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[11]  S. Kapur,et al.  Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. , 2000, The American journal of psychiatry.

[12]  D. Paleacu,et al.  Re: The apolipoprotein E epsilon4 allele increases the risk of drug-induced hallucinations in Parkinson's disease. , 2000, Clinical neuropharmacology.

[13]  C. Tanner,et al.  Early dopaminergic drug-induced hallucinations in parkinsonian patients , 1998, Neurology.

[14]  P. Riederer,et al.  Responsibility of extrastriatal areas for the appearance of psychotic symptoms (Clinical and biochemical human post-mortem findings) , 2005, Journal of Neural Transmission.

[15]  P J Feustel,et al.  Longitudinal outcome of Parkinson’s disease patients with psychosis , 2003, Neurology.

[16]  M. Mazurek,et al.  Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone , 1999, Neurology.

[17]  A. Destée,et al.  Retinal involvement in dementia with Lewy bodies: A clue to hallucinations? , 2003, Annals of neurology.

[18]  G. Glover,et al.  Altered cortical visual processing in PD with hallucinations , 2004, Neurology.

[19]  C. Goetz,et al.  Pharmacology of hallucinations induced by long-term drug therapy. , 1982, The American journal of psychiatry.

[20]  I. Shiah,et al.  Ziprasidone in the treatment of Parkinson’s disease psychosis , 2006, European Psychiatry.

[21]  J. Ramírez-Bermúdez,et al.  Aripiprazole in psychosis associated with Parkinson's disease. , 2005, The Journal of neuropsychiatry and clinical neurosciences.

[22]  C. Normann,et al.  Psychosis during Chronic Levodopa Therapy Triggered by the New Antidepressive Drug Mirtazapine , 1997, Pharmacopsychiatry.

[23]  C. Goetz,et al.  Hallucinations in Parkinson disease in the prelevodopa era , 2006, Neurology.

[24]  D. Calne,et al.  Treatment of Dopaminomimetic Psychosis in Parkinson's Disease with Electroconvulsive Therapy , 1988, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[25]  A. Crawley,et al.  Donepezil for dementia in Parkinson’s disease: a randomised, double blind, placebo controlled, crossover study , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[26]  S. Papapetropoulos.  Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments. , 2006, Clinical neuropharmacology.

[27]  S. Bernardi,et al.  Antidepressant use in treatment of psychosis with comorbid depression in Parkinson's disease , 2007, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[28]  S. Minoshima,et al.  In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease , 1996, Annals of neurology.

[29]  S. Grill,et al.  Psychiatric comorbidities in patients with Parkinson disease and psychosis , 2004, Neurology.

[30]  H. Berendse,et al.  Management of psychosis in Parkinson's disease , 2001, Current opinion in neurology.

[31]  Stephen M Stahl,et al.  Brain circuits determine destiny in depression: a novel approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major depressive disorder. , 2003, The Journal of clinical psychiatry.

[32]  B. Ford,et al.  Risperidone in Parkinson's disease , 1994, The Lancet.

[33]  S. Stahl.  Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action. , 2001, The Journal of clinical psychiatry.

[34]  C. Byrne,et al.  Schizophrenia, the metabolic syndrome and diabetes , 2004, Diabetic medicine : a journal of the British Diabetic Association.

[35]  E. Perry,et al.  Acetylcholine in mind: a neurotransmitter correlate of consciousness? , 1999, Trends in Neurosciences.

[36]  G. Nikkhah,et al.  Subthalamic nucleus deep brain stimulation in elderly patients – analysis of outcome and complications , 2007, BMC neurology.

[37]  J. Friedman,et al.  Risperidone and parkinson's disease , 2002, Movement disorders : official journal of the Movement Disorder Society.

[38]  M. Kunik,et al.  The use of risperidone for psychosis and agitation in demented patients with Parkinson's disease. , 1997, The Journal of neuropsychiatry and clinical neurosciences.

[39]  D. Aarsland,et al.  Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study , 2002, Journal of neurology, neurosurgery, and psychiatry.

[40]  V. Lerner,et al.  Successful Use of Donepezil for the Treatment of Psychotic Symptoms in Patients With Parkinson's Disease , 2002, Clinical neuropharmacology.

[41]  V. Voon,et al.  Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease. , 2006, Archives of neurology.

[42]  G. Fénelon,et al.  Hallucinations in Parkinson's disease: A follow‐up study , 2005, Movement disorders : official journal of the Movement Disorder Society.

[43]  C. Peretz,et al.  Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson’s disease , 2004, Journal of Neural Transmission.

[44]  W. Oertel,et al.  Ondansetron Treatment of L-dopa-induced Psychosis , 1996, Neurology.

[45]  H. Klawans,et al.  Levodopa-induced psychosis: a kindling phenomenon. , 1978, The American journal of psychiatry.

[46]  A. Fitton,et al.  Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia. , 1994, Drugs.

[47]  Enrico Marchioni,et al.  Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.

[48]  P. D'Ath,et al.  Risperidone for psychotic and behavioural symptoms in Lewy body dementia , 1995, The Lancet.

[49]  R. Kessler,et al.  Lifetime prevalence, demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a US community sample. The National Comorbidity Survey. , 1996, Archives of general psychiatry.

[50]  H. Frieling,et al.  Treating dopamimetic psychosis in Parkinson's disease: Structured review and meta-analysis , 2007, European Neuropsychopharmacology.

[51]  J. Jenner,et al.  Effectiveness of cognitive therapy with coping training for persistent auditory hallucinations a retrospective study of attenders of a psychiatric out‐patient department , 1998, Acta psychiatrica Scandinavica.

[52]  A. Korczyn,et al.  Auditory hallucinations in Parkinson’s disease , 1998, Journal of neurology, neurosurgery, and psychiatry.

[53]  R. Remick,et al.  Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis , 1990, Neurology.

[54]  J. Larsen,et al.  Sleep Disorders in Patients with Parkinson’s Disease , 2001, CNS drugs.

[55]  G. Albani,et al.  Visual hallucinations in Parkinson's disease: Clues to separate origins , 2006, Journal of the Neurological Sciences.

[56]  Deborah C Mash,et al.  Cortical and amygdalar Lewy body burden in Parkinson's disease patients with visual hallucinations. , 2006, Parkinsonism & related disorders.

[57]  J. Growdon,et al.  Clozapine and risperidone treatment of psychosis in Parkinson's disease. , 2000, The Journal of neuropsychiatry and clinical neurosciences.

[58]  M. Okun,et al.  Rebound psychosis: Effect of discontinuation of antipsychotics in Parkinson's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.

[59]  C. Saller,et al.  Seroquel: biochemical profile of a potential atypical antipsychotic , 2005, Psychopharmacology.

[60]  G. Halliday,et al.  Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. , 2002, Brain : a journal of neurology.

[61]  J. Friedman,et al.  Long‐term outcome of quetiapine use for psychosis among parkinsonian patients , 2003, Movement disorders : official journal of the Movement Disorder Society.

[62]  P. Perozzo,et al.  Chronic Deep Brain Stimulation of the Subthalamic Nucleus for Parkinson’s Disease: Effects on Cognition, Mood, Anxiety and Personality Traits , 2006, European Neurology.

[63]  J. Friedman,et al.  Treatment of Psychosis in Parkinson’s Disease , 2003, Drug safety.

[64]  C. Schönfeldt-Lecuona,et al.  Aripiprazole and Parkinson's disease psychosis. , 2004, The American journal of psychiatry.

[65]  Jacob Gordon,et al.  Clozapine in Parkinson's Disease Psychosis: 5-Year Follow-up Review , 2003, Clinical neuropharmacology.

[66]  W. Poewe,et al.  Scales to assess psychosis in Parkinson's disease: Critique and recommendations , 2008, Movement disorders : official journal of the Movement Disorder Society.

[67]  M. Farrer,et al.  Phenotypic associations of tau and ApoE in Parkinson's disease , 2007, Neuroscience Letters.

[68]  M. Oechsner,et al.  Parenteral ziprasidone: a new atypical neuroleptic for emergency treatment of psychosis in Parkinson's disease? , 2005, Human psychopharmacology.

[69]  K. Gwinn‐Hardy,et al.  Diagnostic criteria for psychosis in Parkinson's disease: Report of an NINDS, NIMH work group , 2007, Movement disorders : official journal of the Movement Disorder Society.

[70]  W. Ondo,et al.  Double‐blind, placebo‐controlled, unforced titration parallel trial of quetiapine for dopaminergic‐induced hallucinations in Parkinson's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.

[71]  Bettina Schrader,et al.  Two‐year follow‐up of subthalamic deep brain stimulation in Parkinson's disease , 2003, Movement disorders : official journal of the Movement Disorder Society.

[72]  J. Friedman,et al.  Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson’s disease , 2002, Biological Psychiatry.

[73]  J. Sanchez-Ramos,et al.  Visual hallucinations associated with Parkinson disease. , 1996, Archives of neurology.

[74]  W. van Tilburg,et al.  Visual Hallucinations and Delirium During Treatment with Amantadine (Symmetrel) , 1975, Journal of the American Geriatrics Society.

[75]  C. Schönfeldt-Lecuona,et al.  Ziprasidone in Parkinson's Disease Psychosis , 2004, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[76]  E. Wolters,et al.  Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease , 1996, Neurology.

[77]  M. Hutchinson,et al.  Cholinesterase inhibition in Parkinson's disease. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[78]  G. Lenzi,et al.  Donepezil in the treatment of hallucinations and delusions in Parkinson’s disease , 2002, Neurological Sciences.

[79]  I. Ziv,et al.  Involvement of serotonin in clinical features of Parkinson's disease and complications of L-DOPA therapy. , 1996, Advances in neurology.

[80]  I. McKeith,et al.  Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.

[81]  L. Hanoglu,et al.  Electroconvulsive therapy in drug-induced psychiatric states and neuroleptic malignant syndrome. , 2005, The journal of ECT.

[82]  S. Factor,et al.  Threatening auditory hallucinations and Cotard syndrome in Parkinson disease. , 2004, Clinical neuropharmacology.

[83]  P. McGorry,et al.  Psychoeducation in first-episode psychosis: a therapeutic process. , 1995, Psychiatry.

[84]  I. McKeith,et al.  A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia , 2001, International journal of geriatric psychiatry.

[85]  D. Paleacu,et al.  Association between family history of dementia and hallucinations in Parkinson disease , 2005, Neurology.

[86]  J. Friedman,et al.  The Role of Atypical Antipsychotics in the Treatment of Movement Disorders , 1999 .

[87]  J. Carter,et al.  Living with a person who has parkinson's disease: The Spouse's perspective by stage of disease , 1998, Movement disorders : official journal of the Movement Disorder Society.

[88]  H. Morris,et al.  Aripiprazole associated with severe exacerbation of Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.

[89]  J. Zarranz,et al.  Use of Ziprasidone in Parkinsonian Patients With Psychosis , 2005, Clinical neuropharmacology.

[90]  S. Factor,et al.  Combined clozapine and electroconvulsive therapy for the treatment of drug-induced psychosis in Parkinson's disease. , 1995, The Journal of neuropsychiatry and clinical neurosciences.

[91]  R. Hemmingsen,et al.  Dopaminergic sensitization: Implications for the pathogenesis of schizophrenia , 1997, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[92]  G. Wooten,et al.  Preliminary FMRI evidence of visual system dysfunction in Parkinson's disease patients with visual hallucinations. , 2006, The Journal of neuropsychiatry and clinical neurosciences.

[93]  S. Leurgans,et al.  Olanzapine and clozapine , 2000, Neurology.

[94]  Lon S Schneider,et al.  Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. , 2005, JAMA.

[95]  P. Rondot,et al.  Mental disorders in Parkinson's disease after treatment with L-DOPA. , 1984, Advances in neurology.

[96]  S. Papapetropoulos,et al.  Factors associated with drug–induced visual hallucinations in Parkinson's disease , 2005, Journal of Neurology.

[97]  H. Fernandez,et al.  Course, Prognosis, and Management of Psychosis in Parkinson's Disease: Are Current Treatments Really Effective? , 2008, CNS Spectrums.

[98]  A. Glassman.  Schizophrenia, antipsychotic drugs, and cardiovascular disease. , 2005, The Journal of clinical psychiatry.

[99]  J. Cummings,et al.  Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. , 1999, Archives of neurology.

[100]  D. Aarsland,et al.  Predictors of Nursing Home Placement in Parkinson's Disease: A Population‐Based, Prospective Study , 2000, Journal of the American Geriatrics Society.

[101]  J. Friedman,et al.  Open‐label flexible‐dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.

[102]  J. Jankovic,et al.  Olanzapine treatment for dopaminergic‐induced hallucinations , 2002, Movement disorders : official journal of the Movement Disorder Society.

[103]  S. Stahl.  Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, "Goldilocks" actions at dopamine receptors. , 2001, The Journal of clinical psychiatry.

[104]  S. Leurgans,et al.  Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson's disease , 1999, Movement disorders : official journal of the Movement Disorder Society.

[105]  E. Wolters,et al.  Intrinsic and extrinsic psychosis in Parkinson's disease , 2001, Journal of Neurology.

[106]  D. Fekkes,et al.  Serotonin and amino acids: partners in delirium pathophysiology? , 2000, Seminars in clinical neuropsychiatry.

[107]  R. Camicioli,et al.  Apolipoprotein E ϵ4 and catechol‐O‐methyltransferase alleles in autopsy‐proven Parkinson's disease: Relationship to dementia and hallucinations , 2005, Movement disorders : official journal of the Movement Disorder Society.

[108]  J. Friedman,et al.  The management of the levodopa psychoses. , 1991, Clinical neuropharmacology.

[109]  S. Factor.  Pharmacology of atypical antipsychotics. , 2002, Clinical neuropharmacology.

[110]  G. Stebbins,et al.  Risk factors for nursing home placement in advanced Parkinson's disease , 1993, Neurology.

[111]  C. Tanner,et al.  Polysomnographic sleep measures in Parkinson's disease patients with treatment‐induced hallucinations , 1993, Annals of neurology.

[112]  I. Bodis-Wollner.  Visual deficits related to dopamine deficiency in experimental animals and Parkinson's disease patients , 1990, Trends in Neurosciences.

[113]  J. Schein,et al.  Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. , 1998, The Journal of clinical psychiatry.

[114]  R. Marconi,et al.  Quetiapine and Clozapine in Parkinsonian Patients With Dopaminergic Psychosis , 2004, Clinical neuropharmacology.

[115]  Y. Agid,et al.  Parkinson’s disease and sleepiness: An integral part of PD , 2002, Neurology.

[116]  J. Rabey,et al.  Effect of quetiapine in psychotic Parkinson's disease patients: A double‐blind labeled study of 3 months' duration , 2007, Movement disorders : official journal of the Movement Disorder Society.

[117]  E. Melamed,et al.  Ondansetron for hallucinosis in advanced Parkinson's disease , 1993, The Lancet.

[118]  Nir Giladi,et al.  Risk factors for dementia, depression and psychosis in long-standing Parkinson's disease , 2000, Journal of Neural Transmission.

[119]  David R Williams,et al.  Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study , 2005, The Lancet Neurology.

[120]  S. Factor,et al.  The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia , 2002, Movement disorders : official journal of the Movement Disorder Society.

[121]  R. Borison,et al.  ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group. , 1996, Journal of clinical psychopharmacology.

[122]  I G McKeith,et al.  Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: Preliminary findings from an open trial , 2001, Movement disorders : official journal of the Movement Disorder Society.

[123]  A. Alessandri,et al.  Risperidone in levodopa‐induced psychosis in advanced parkinson's disease: An open‐label, long‐term study , 1997, Movement disorders : official journal of the Movement Disorder Society.

[124]  C. Goetz,et al.  Coping strategies for visual hallucinations in Parkinson's disease , 2003, Movement disorders : official journal of the Movement Disorder Society.

[125]  J. Mellers,et al.  Psychosis in Parkinson’s disease: ‘between a rock and a hard place’ , 2000 .

[126]  H. Klawans,et al.  Serotonergically active agents in levodopa-induced psychiatric toxicity reactions. , 1983, Advances in neurology.

[127]  S. Stahl,et al.  The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. , 2003, The Journal of clinical psychiatry.

[128]  N. Tarrier,et al.  Is there evidence that cognitive behaviour therapy is an effective treatment for schizophrenia? A cautious or cautionary tale? , 2004, Behaviour research and therapy.

[129]  D. Aarsland,et al.  Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia , 2003, International journal of geriatric psychiatry.

[130]  G. Meco,et al.  Risperidone for hallucinations in levodopa-treated Parkinson's disease patients , 1994, The Lancet.

[131]  J. Rabey,et al.  Long-term Follow-up (24 Months) of Quetiapine Treatment in Drug-induced Parkinson Disease Psychosis , 2006, Clinical neuropharmacology.

[132]  N. Keltner,et al.  Biological perspectives. Aripiprazole: a third generation of antipsychotics begins? , 2002, Perspectives in psychiatric care.

[133]  G. Fénelon,et al.  Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. , 2000, Brain : a journal of neurology.

[134]  D. Kömpf,et al.  A study of visual hallucinations in patients with Parkinson’s disease , 1997, Journal of Neurology.

[135]  C. Juri,et al.  Quetiapine for Insomnia in Parkinson Disease: Results From an Open-Label Trial , 2005, Clinical neuropharmacology.

[136]  A. Lang,et al.  Antidepressants in the treatment of psychosis with comorbid depression in Parkinson disease. , 2004, Clinical neuropharmacology.

[137]  S. Factor,et al.  Parkinson's disease: drug-induced psychiatric states. , 1995, Advances in neurology.

[138]  Fabrizio Stocchi,et al.  Factors impacting on quality of life in Parkinson's disease: Results from an international survey , 2002, Movement disorders : official journal of the Movement Disorder Society.

[139]  E. Sofić,et al.  Serum prolactin, leptin, lipids and lipoproteins levels during antipsychotics treatment in Parkinson's disease and related psychosis. , 2006, Medicinski arhiv.

[140]  M. Ceccaldi,et al.  Nonmotor fluctuations in Parkinson’s disease: Frequent and disabling , 2002, Neurology.

[141]  J. Friedman,et al.  Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. , 1995, The Journal of clinical psychiatry.

[142]  A. Destée,et al.  Clozapine in drug induced psychosis in Parkinson’s disease: a randomised, placebo controlled study with open follow up , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[143]  S. Leurgans,et al.  The malignant course of "benign hallucinations" in Parkinson disease. , 2006, Archives of neurology.

[144]  M. Okun,et al.  Psychosis in Parkinson’s Disease , 2004, Journal of geriatric psychiatry and neurology.

[145]  J. Friedman,et al.  Aripiprazole for Drug-Induced Psychosis in Parkinson Disease: Preliminary Experience , 2004, Clinical neuropharmacology.

[146]  G. Kiziltan,et al.  Relationship between age and subtypes of psychotic symptoms in Parkinson's disease , 2007, Journal of Neurology.

[147]  R. Bullock,et al.  Rivastigmine for the Treatment of Dementia and Visual Hallucinations Associated with Parkinson's Disease: A Case Series , 2002, Current medical research and opinion.

[148]  P. D. De Deyn,et al.  Risperidone in the treatment of dopamine‐induced psychosis in Parkinson's disease: An open pilot trial , 2000, Movement disorders : official journal of the Movement Disorder Society.

[149]  B. Ott,et al.  Exacerbation of parkinsonism by tacrine. , 1992, Clinical neuropharmacology.

[150]  E. Melamed,et al.  Psychosis in advanced Parkinson's disease , 1995, Neurology.

[151]  S. Leurgans,et al.  Prospective longitudinal assessment of hallucinations in Parkinson’s disease , 2001, Neurology.

[152]  J. Pearce.  Longus cervicis colli "myositis" (syn: retropharyngeal tendinitis) , 1996, Journal of neurology, neurosurgery, and psychiatry.

[153]  J. Friedman,et al.  Diabetes mellitus among parkinsonian patients treated chronically with clozapine. , 2004, Parkinsonism & related disorders.

[154]  A. David,et al.  Reality monitoring and visual hallucinations in Parkinson’s disease , 2003, Neuropsychologia.

[155]  P. Weiden,et al.  Best clinical practice with ziprasidone: update after one year of experience. , 2002, Journal of psychiatric practice.

[156]  H. Stefan,et al.  Postoperative multichannel magnetoencephalography in patients with recurrent seizures after epilepsy surgery , 1998, Acta neurologica Scandinavica.

[157]  Kiyoharu Inoue,et al.  The Beneficial Effect of Donepezil on Visual Hallucinations in Three Patients with Parkinson's Disease , 2003, Journal of geriatric psychiatry and neurology.

[158]  A. Korczyn,et al.  Apolipoprotein ɛ4 advances appearance of psychosis in patients with Parkinson's disease , 2006 .

[159]  D. Chan.  The art of treating Parkinson disease in the older patient. , 2003, Australian family physician.

[160]  N. Moore,et al.  The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. , 1992, The Journal of pharmacology and experimental therapeutics.

[161]  J. Friedman,et al.  THE NONMOTOR PROBLEMS OF PARKINSON'S DISEASE , 2000 .

[162]  P. Whitehouse.  Clinical and neurochemical consequences of neuronal loss in the nucleus basalis of Meynert in Parkinson's disease and Alzheimer's disease. , 1987, Advances in neurology.